Rose Bhatt

Rose Bhatt leads a rare cancer advocacy organization that fights to accelerate research and treatment access for patients with cancers lacking standard-of-care options. Her policy work contributed to expansion of the Orphan Drug Act and the creation of FDA Breakthrough Therapy Designation pathways. She has advocated for inclusion of rare cancer patients in tumor agnostic biomarker-driven trials such as NCI-MATCH and ASCO TAPUR. Her coalition-building across rare disease communities has amplified patient voices in oncology drug development and regulatory decision-making.